Evidence map›Paper›PMID 42312174›Full record

ArticleACS pharmacology & translational science2026

Repurposing FDA-Approved Drugs as Potential Inhibitors of Feline Infectious Peritonitis Virus 3CL

Varanya Lueangaramkul, Natjira Mana, Nattarat Thangthamniyom, Ploypailin Semkum, Porntippa Lekcharoensuk, Vudhiporn Limprasutr, Sirin Theerawatanasirikul

Abstract read
In one paragraph

Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Varanya LueangaramkulGraduate Program in Animal Health and Biomedical Sciences, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand.ORCID https://orcid.org/0009-0001-5953-976X
Natjira ManaDepartment of Microbiology and Immunology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand.
Nattarat ThangthamniyomDepartment of Microbiology and Immunology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand.
Ploypailin SemkumDepartment of Microbiology and Immunology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand.
Porntippa LekcharoensukDepartment of Microbiology and Immunology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand.ORCID https://orcid.org/0000-0001-5595-3296
Vudhiporn LimprasutrDepartment of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
Sirin TheerawatanasirikulDepartment of Anatomy, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand.ORCID https://orcid.org/0000-0002-6912-9764

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Feline infectious peritonitis (FIP), caused by feline coronavirus (FCoV) remains a critical therapeutic challenge with no universally approved treatments. We employed a drug repurposing strategy targeting the viral main protease (3CL

Indexed as

antiviral synergycombination therapycytokine modulationdrug repurposingFDA-approved drugsfeline infectious peritonitis virus (FIPV)

Identifiers

PMID42312174
PMCPMC13270442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.